07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer ADAM9; CUB domain containing protein 1 (CDCP1) Studies in patient samples and mice suggest inhibiting...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) ADAM9; ADAM10; amyloid precursor protein (APP) Cell culture studies suggest inhibiting the metalloproteinase ADAM9...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE,...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease ...